Revenue
2022
2023
2024
2025
Anavex Life Sciences Corp. (AVXL)
Price$2.86Cached quote
Net income
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2012
2013
2014
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $37.6M | $41.8M | $43.7M | $37.9M | $33.0M | $25.2M | $22.3M | $13.3M | $10.7M | $7.3M | $2.3M | $732,395 | $263,847 | $2.7M | $2.6M | $2.7M | — | — | — | — | — |
| Operating expenses | $51.4M | $52.9M | $55.8M | $51.0M | $42.0M | $31.1M | $29.1M | $19.3M | $15.7M | $15.6M | $7.1M | $3.0M | — | — | — | — | — | — | — | — | — |
| Operating income | −$51.4M | −$52.9M | −$55.8M | −$51.0M | −$42.0M | −$31.1M | — | — | — | — | — | −$3.0M | −$2.1M | −$4.3M | −$6.2M | −$5.6M | — | — | — | — | — |
| EBITDA | −$46.4M | −$43.0M | −$46.5M | −$47.6M | — | — | — | — | — | — | — | −$3.0M | −$2.1M | −$4.3M | −$6.2M | −$5.6M | — | — | — | — | — |
| Net income | −$46.4M | −$43.0M | −$47.5M | −$48.0M | −$37.9M | −$26.3M | −$26.3M | −$17.3M | −$13.5M | −$14.7M | −$12.1M | −$10.0M | −$3.7M | −$8.3M | −$7.3M | −$8.8M | −$5.5M | −$5.4M | −$1.6M | −$25,532 | −$91,625 |
| Basic EPSper basic share | -$0.54 | -$0.52 | -$0.60 | -$0.62 | -$0.54 | -$0.45 | -$0.54 | -$0.39 | -$0.33 | -$0.42 | -$0.65 | -$1.02 | -$0.48 | — | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$0.54 | -$0.52 | -$0.60 | -$0.62 | -$0.54 | -$0.45 | -$0.54 | -$0.39 | -$0.33 | -$0.42 | -$0.65 | -$1.02 | -$0.48 | -$1.16 | -$1.16 | -$1.64 | — | — | — | — | — |
Owners
Reported shareholders
8.69%of listed shares
BlackRock, Inc.8.06M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 8.69%8.06M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.37%4.05M shares |
TWO SIGMA INVESTMENTS, LP | 3.29%3.05M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.60%2.41M shares |
STATE STREET CORP | 2.07%1.92M shares |
MISSLING CHRISTOPHER U | ≈1.63%1.51M shares |
FEDERATED HERMES, INC. | 1.16%1.07M shares |
AQR CAPITAL MANAGEMENT LLC | 1.04%963.01K shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 1.02%948.63K shares |
Summit Financial, LLC | 0.98%909.43K shares |
GOLDMAN SACHS GROUP INC | 0.96%890.63K shares |
MARSHALL WACE, LLP | 0.96%889.52K shares |
NORTHERN TRUST CORP | 0.85%784.49K shares |
BARCLAYS PLC | 0.81%754.23K shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.79%734.8K shares |
BANK OF AMERICA CORP /DE/ | 0.71%654.3K shares |
VANGUARD FIDUCIARY TRUST CO | 0.67%621.45K shares |
UBS Group AG | 0.67%620.37K shares |
Private Advisor Group, LLC | 0.54%504K shares |
LPL Financial LLC | 0.44%406.11K shares |
Percentages use 92.7M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data